You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

GL-ONC1

Showing 1 - 25 of 4,171
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian Cancer, Peritoneal Carcinomatosis, Fallopian Tube Cancer Trial in Newport Beach, Orlando (GL-ONC1 alone, or in

Completed
  • Ovarian Cancer
  • +2 more
  • GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumab
  • Newport Beach, California
  • +1 more
Jan 3, 2023

Lung Cancer Trial in New York (GL-ONC1)

Active, not recruiting
  • Lung Cancer
  • GL-ONC1
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Feb 7, 2022

Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer Trial in Orlando, Albuquerque

Recruiting
  • Platinum-resistant Ovarian Cancer
  • +6 more
  • olvimulogene nanivacirepvec
  • +3 more
  • Orlando, Florida
    AdventHealth Cancer Institute
Sep 1, 2022

Solid Organ Cancers Trial in La Jolla (GL-ONC1)

Terminated
  • Solid Organ Cancers
  • GL-ONC1
  • La Jolla, California
    UC San Diego Moores Cancer Center
Mar 23, 2020

Advanced Stage Cancer (Solid Tumor Disease for 4 Patients), Acute Myeloid Leukemia (6 Patients) Trial in Orlando (GL-ONC1)

No longer available
  • Advanced Stage Cancer (Solid Tumor Disease for 4 Patients)
  • Acute Myeloid Leukemia (6 Patients)
  • GL-ONC1
  • Orlando, Florida
    Florida Hospital Cancer Institute
Jul 30, 2019

First in Man Study to Evaluate Initial Safety Trial in Leeds (GL-0719, Placebo)

Recruiting
  • First in Man Study to Evaluate Initial Safety
  • Leeds, United Kingdom
    Labcorp Clinical Research Unit Ltd
Sep 9, 2022

Glabellar Frown Lines Trial in Miami (AI-09, Vehicle)

Recruiting
  • Glabellar Frown Lines
  • AI-09
  • Vehicle
  • Miami, Florida
    Baumann Cosmetic & Research Institute
Oct 11, 2022

Non Small Cell Lung Cancer Trial in Davis, Orlando, Columbus (ONC-392, Docetaxel)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Davis, California
  • +2 more
Jan 5, 2023

Endometrial Cancer, Metastasis Trial (Atezolizumab, ONC201)

Not yet recruiting
  • Endometrial Cancer
  • Metastasis
  • (no location specified)
Sep 12, 2022

Metastatic Colorectal Cancer Trial in Providence (Dose level 1 ONC201 625mg, Dose level 2 ONC201 500mg, Dose level 3 ONC201

Terminated
Has Results
  • Metastatic Colorectal Cancer
  • Dose level 1 ONC201 625mg
  • +2 more
  • Providence, Rhode Island
    Lifespan Cancer Institute: The Miriam and Rhode Island Hospitals
May 25, 2022

Colorectal Adenomatous Polyp, Colorectal Carcinoma, Familial Adenomatous Polyposis Trial in United States (procedure, drug,

Not yet recruiting
  • Colorectal Adenomatous Polyp
  • +3 more
  • Biopsy
  • +5 more
  • Ann Arbor, Michigan
  • +4 more
Jan 3, 2023

Metastatic Castration-resistant Prostate Cancer Trial (ONC-392, lutetium Lu 177 vipivotide tetraxetan 7.4 GBq (200 mCi), IV

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • ONC-392
  • lutetium Lu 177 vipivotide tetraxetan 7.4 GBq (200 mCi), IV infusion, Q6W for up to 6 doses.
  • (no location specified)
Dec 27, 2022

Myeloproliferative Tumor Trial in Worldwide (Navitoclax, Ruxolitinib, Celecoxib)

Recruiting
  • Myeloproliferative Neoplasm
  • Duarte, California
  • +41 more
Feb 1, 2023

Ocular Hypertension, Open Angle Glaucoma Trial in Newport Beach (JV-GL1, Latanoprost 0.005% Ophthalmic Solution)

Active, not recruiting
  • Ocular Hypertension
  • Open Angle Glaucoma
  • JV-GL1
  • Latanoprost 0.005% Ophthalmic Solution
  • Newport Beach, California
    Eye Research Foundation
Mar 28, 2022

Postoperative Thirst Trial in Gloucester (Flavoured ice lollies (popsicles), Water)

Completed
  • Postoperative Thirst
  • Flavoured ice lollies (popsicles)
  • Water
  • Gloucester, Gloucestershire, United Kingdom
    Gloucestershire Royal Hospital
Aug 21, 2023

Squamous Cell Carcinoma of the Oral Cavity Trial in Worldwide (GL-0817, Hiltonol, Sargramostim)

Completed
  • Squamous Cell Carcinoma of the Oral Cavity
  • Baltimore, Maryland
  • +32 more
Mar 4, 2022

Diffuse Midline Glioma (DMG), Glioblastoma, Recurrent Ependymoma Trial in San Francisco, Ann Arbor, Zürich (ONC206, Standard of

Recruiting
  • Diffuse Midline Glioma (DMG)
  • +7 more
  • ONC206
  • Standard of Care Radiation Therapy
  • San Francisco, California
  • +2 more
Sep 13, 2022

Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma Trial in Australia (AI-061)

Not yet recruiting
  • Melanoma
  • +16 more
  • Darlinghurst, New South Wales, Australia
  • +3 more
May 12, 2023

Lymphoma, Head Neck Cancer Trial in Gloucester (spectroscopic measurement, FNA biopsy, histopathology and cytology)

Not yet recruiting
  • Lymphoma
  • Head and Neck Cancer
  • spectroscopic measurement
  • +2 more
  • Gloucester, Gloucestershire, United Kingdom
    Gloucestershire Hospitals NHS Foundation Trust
May 26, 2022

Geographic Atrophy Insights (i-GAIN) Natural History Study

Recruiting
  • Dry Age-related Macular Degeneration
  • +6 more
    • Belfast, United Kingdom
    • +11 more
    Mar 22, 2023

    RAman For Thyroid cancER

    Not yet recruiting
    • Thyroid Diseases
    • Thyroid Cancer
    • thyroid lobectomy
    • Raman spectroscopy probe measurement
    • Gloucester, Gloucestershire, United Kingdom
      Biophotonics Research Unit
    Mar 14, 2022

    Advanced Cancer Trial in United States (AGEN1777, a PD-1 inhibitor)

    Recruiting
    • Advanced Cancer
    • Grand Rapids, Michigan
    • +5 more
    Jun 8, 2022

    Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma Trial (ONC-392, Pembrolizumab)

    Recruiting
    • Ovarian Cancer
    • +3 more
    • Goodyear, Arizona
    • +19 more
    Dec 26, 2022

    Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Supratentorial Glioblastoma Trial in Los Angeles (drug, radiation,

    Withdrawn
    • Recurrent Glioblastoma
    • +3 more
    • Akt/ERK Inhibitor ONC201
    • +2 more
    • Los Angeles, California
      UCLA / Jonsson Comprehensive Cancer Center
    May 10, 2021

    Moderate to Severe Glabellar Lines Trial (AGN-151586, Placebo)

    Not yet recruiting
    • Moderate to Severe Glabellar Lines
    • (no location specified)
    Nov 22, 2023